text_1: Alirocumab treatment reduces apo(a) fractional clearance rate.
text_2: The regulation of plasma Lp(a) levels, including the role of LDL receptors in the clearance of Lp(a), is poorly defined, and no mechanistic studies of the Lp(a) lowering by alirocumab in humans have been published to date.